TCMD at a glance
TACTILE SYSTEMS TECHNOLOGY INC (TCMD, SEC CIK 1027838) filed its latest 10-K annual report on February 17, 2026, a 10-Q quarterly report on November 2, 2026, an 8-K current report on November 2, 2026 and Form 4 insider filings as recently as November 9, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), TACTILE SYSTEMS TECHNOLOGY INC (TCMD) reported revenue of $329.5 million (up 12.5% from FY2024) and net income of $19.1 million. Diluted EPS was $0.82.
- As of September 30, 2026, 27 institutional investment managers tracked by SignalX reported holding TACTILE SYSTEMS TECHNOLOGY INC (TCMD) shares worth $212.2 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by BURKE WILLIAM W on November 4, 2026 of 5,000 shares at $27.00 per share.
- In the last 90 days, TCMD insiders reported 0 open-market purchases ($0) and 2 open-market sales ($255K) on Form 4, a net sale of $255K.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $329.5M
- +12.5% vs prior year
- Insiders · 90 days
- 0 buys · 2 sells
- Net −$255K
- 13F holders
- 27 funds
- $212.2M · −1 vs prior quarter
- Latest 8-K
- Nov 2, 2026
- Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Risk Factors
- No material changes from the December 31, 2025 Form 10-K risk factors
- Carried-forward business, financial-condition, and future-results risks remain applicable
- Annual Report risk disclosures remain the primary source for specific operational, regulatory, market, and financial risks
Management Discussion & Analysis
- Quarterly revenue $91.9M, up 7% YoY from $85.8M
- Gross margin 77% vs 76% YoY, net income $7.2M vs $8.2M
- Best line lymphedema products: $81.8M, up 13%; airway clearance worst: $10.0M, down 25%
- Cash $75.1M; nine-month operating cash flow $14.9M vs $25.5M, with $12.5M stock repurchases
- AffloVest inventory transition pressured near-term revenue; IT implementation expected through remainder of 2026
AI summary of the TCMD 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Press release announces Tactile Systems’ results for the most recently completed fiscal quarter
- Investor focus: quarterly operating performance and financial condition, with detailed figures in the referenced release
Item EX-99.1: Item EX-99.1
- Q3 revenue $91.9M, up 7%, led by lymphedema growth of 13% to $81.8M
- Gross margin expanded to 77%, but operating expenses rose 13% to $60.9M, reducing net income to $7.2M from $8.2M
Item 2.02: Results of Operations and Financial Condition
- Press release announces Tactile Systems’ results for the most recently completed fiscal quarter
- Investor-relevant operating figures and financial condition details are contained in the accompanying press release exhibit
Item EX-99.1: Item EX-99.1
- Q2 revenue rose 9% to $85.7M, led by lymphedema growth of 12% to $73.6M
- Gross margin expanded to 76% from 75%, while net income increased to $7.8M from $3.2M
Item 7.01: Regulation FD Disclosure
- Press release announces a distribution agreement, potentially expanding Tactile Systems’ commercial reach
- Agreement terms, counterparties, and financial impact require review of Exhibit 99.1
Item 8.01: Other Events
- Exclusive VA/DoD distribution rights for MyoSleeve, expanding TCMD’s compression portfolio into earlier-stage chronic swelling treatment
- $3 million upfront payment to ElastiMed, plus minimum purchase obligations and marketing commitments
Item EX-99.1: Item EX-99.1
- Exclusive U.S. VA and DoD distribution rights for ElastiMed’s FDA-cleared MyoSleeve wearable compression device
- $3 million upfront payment plus minimum purchase obligations and marketing commitments, creating near-term cash and execution requirements
AI summaries of TCMD 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for TCMD
Don't miss the next TCMD filing
- Alerts as it files. A push when TCMD files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut TCMD, by share count.
- Ask anything. An AI agent that reads every TCMD filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| BURKE WILLIAM W | Sell | Nov 4, 2026 | 5,000 | $27.00 |
| Kiewiet Stephen A. | A | Nov 4, 2026 | 6,438 | - |
| King Laura G. | Sell | Nov 3, 2026 | 4,800 | $25.00 |
| Dodd Sheri Louise | Sell | Aug 10, 2026 | 10,978 | $29.44 |
| Pearson Andrea | A | May 6, 2026 | 6,521 | - |
| BURKE WILLIAM W | A | May 6, 2026 | 6,521 | - |
| Asbury Valerie L. | A | May 6, 2026 | 6,521 | - |
| Huggenberger Raymond | A | May 6, 2026 | 6,521 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $293.0M | $329.5M |
| Gross Profit | - | $216.7M | $250.1M |
| Operating Income | - | $22.2M | $29.3M |
| Net Income | - | $17.0M | $19.1M |
| Gross Margin | - | 74.0% | 75.9% |
| Op. Margin | - | 7.6% | 8.9% |
| Net Margin | - | 5.8% | 5.8% |
| Balance Sheet | |||
| Total Assets | $281.4M | $297.9M | $273.9M |
| Equity | $193.6M | $216.6M | $218.9M |
| ROE | - | 7.8% | 8.7% |
| Per Share | |||
| EPS | - | $0.70 | $0.82 |
| Cash Flow | |||
| Operating CF | - | $40.7M | $42.8M |
| CapEx | - | $2.4M | $2.4M |
Source: XBRL data in TACTILE SYSTEMS TECHNOLOGY INC (TCMD)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate TCMD share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 27 | $212.2M |
| Q2 2026 | 28 | $265.8M |
| Q1 2026 | 29 | $235.8M |
| Q4 2025 | 28 | $250.9M |
| Q3 2025 | 25 | $131.9M |
| Q2 2025 | 28 | $94.1M |
| Q1 2025 | 25 | $98.8M |
| Q4 2024 | 21 | $83.2M |
- Morgan Stanley+811.1K (+83%)
- Citadel Advisors LLC+49.2K (+88%)
- Goldman Sachs Group+47.7K (+20%)
- Vanguard Portfolio Management LLC+40.5K (+6%)
- Dimensional Fund Advisors+37.4K (+3%)
- Renaissance Technologies LLC−115.1K (-24%)
- Franklin Resources−103.2K (-57%)
- Ameriprise Financial−52.7K (-21%)
- Prudential Financial−29.3K (-17%)
- Wells Fargo & Co−24.8K (-74%)
- FMR LLC (Fidelity)−136.8K
Source: 13F-HR filings on SEC EDGAR (aggregated from 211 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
TCMD filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Nov 9, 2026 | - | - | - |
| 4 | Nov 6, 2026 | - | - | - |
| 4 | Nov 5, 2026 | - | - | - |
| 10-Q | Nov 2, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Nov 2, 2026 | - | Analysis | - |
| 4 | Aug 12, 2026 | - | - | - |
| 10-Q | Aug 10, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 10, 2026 | - | Analysis | - |
| 8-K | Jul 13, 2026 | - | Analysis | - |
| 4 | May 8, 2026 | - | - | |
| 4 | May 8, 2026 | - | - | |
| 4 | May 8, 2026 | - | - | |
| 4 | May 8, 2026 | - | - | |
| 4 | May 8, 2026 | - | - | |
| 4 | May 8, 2026 | - | - | |
| 4 | May 8, 2026 | - | - | |
| 4 | May 8, 2026 | - | - | |
| 8-K | May 7, 2026 | - | Analysis | |
| 10-Q | May 4, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | May 4, 2026 | - | Analysis | - |
| 4 | Mar 11, 2026 | - | - | - |
| 8-K | Mar 9, 2026 | - | Analysis | - |
| 4 | Feb 26, 2026 | - | - | - |
| 4 | Feb 26, 2026 | - | - | - |
| 4 | Feb 26, 2026 | - | - | - |
Related Health Care companies
- ARAY · ACCURAY INCSurgical & Medical Instruments & Apparatus
- ATEC · Alphatec Holdings, Inc.Surgical & Medical Instruments & Apparatus
- ANGO · ANGIODYNAMICS INCSurgical & Medical Instruments & Apparatus
- ANIK · Anika Therapeutics, Inc.Surgical & Medical Instruments & Apparatus
- AORT · ARTIVION, INC.Surgical & Medical Instruments & Apparatus
- ATRC · AtriCure, Inc.Surgical & Medical Instruments & Apparatus
- RCEL · AVITA Medical, Inc.Surgical & Medical Instruments & Apparatus
- BAX · Baxter InternationalSurgical & Medical Instruments & Apparatus
TCMD SEC filings: frequently asked questions
Are TCMD insiders buying or selling?
In the last 90 days, TACTILE SYSTEMS TECHNOLOGY INC (TCMD) officers, directors and 10% owners reported no open-market purchases and 2 open-market sales worth $255,000 by 2 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold TCMD stock?
As of September 30, 2026, the largest TACTILE SYSTEMS TECHNOLOGY INC (TCMD) holders among the 13F filers tracked by SignalX were BlackRock ($42.9 million), Morgan Stanley ($39.9 million), Dimensional Fund Advisors ($25.2 million), Vanguard Capital Management LLC ($21.4 million), Vanguard Portfolio Management LLC ($16.7 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was TCMD's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), TACTILE SYSTEMS TECHNOLOGY INC (TCMD) reported revenue of $329.5 million (up 12.5% from FY2024) and net income of $19.1 million. Diluted EPS was $0.82. The figures come from the XBRL data in the 10-K.
What did TCMD report in its latest 8-K?
TACTILE SYSTEMS TECHNOLOGY INC (TCMD) filed an 8-K on November 2, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Press release announces Tactile Systems’ results for the most recently completed fiscal quarter.
What are the latest TCMD SEC filings?
TACTILE SYSTEMS TECHNOLOGY INC (TCMD) filed its latest 10-K annual report on February 17, 2026, a 10-Q quarterly report on November 2, 2026, an 8-K current report on November 2, 2026 and a Form 4 insider filing on November 9, 2026.
What is TCMD's SEC CIK number?
TACTILE SYSTEMS TECHNOLOGY INC (TCMD)'s SEC Central Index Key (CIK) is 1027838. EDGAR lists every TCMD filing under that number.
Ask anything about TCMD
The research agent reads TCMD's filings, financials, insider trades and 13F holders, then answers with sources.